Effects of statin treatment on cardiac function in patients with chronic heart failure: A meta-analysis of randomized controlled trials

Clinical Cardiology

Volumn 34, Issue 2, 2011, Pages 117-123

  Zhang, Lei ^a   Zhang, Shuning ^a   Jiang, Hong ^a   Sun, Aijun ^a   Zou, Yunzeng ^a,b   Ge, Junbo ^a,b  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BRAIN NATRIURETIC PEPTIDE; CERIVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; BIBLIOGRAPHIC DATABASE; DATA BASE; DRUG EFFECT; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART VENTRICLE REMODELING; HUMAN; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CYTOKINES; FEMALE; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NEUROTRANSMITTER AGENTS; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 79751478734     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20821     Document Type: Article

References (40)

1. Belch JJ, Bridges AB, Scott N, et al. Oxygen free radicals and congestive heart failure. Br Heart J 1991 65 245-248.
2. Vasan RS, Sullivan LM, Roubenoff R, et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: th (Pubitemid 36378485)
3. Packer M,. Neurohormonal interactions and adaptations in congestive heart failure. Circulation 1988 77 721-730. (Pubitemid 18093492)
4. Trochu JN, Mital S, Zhang X, et al. Preservation of NO production by statins in the treatment of heart failure. Cardiovasc Res 2003 60 250-258. (Pubitemid 37412358)
5. Mozaffarian D, Minami E, Letterer RA, et al. The effects of atorvastatin (10 mg) on systemic inflammation in heart failure. Am J Cardiol 2005 96 1699-1704. (Pubitemid 41790394)
6. Pliquett RU, Cornish KG, Zucker IH,. Statin therapy restores sympathovagal balance in experimental heart failure. J Appl Physiol 2003 95 700-704. (Pubitemid 36944294)
7. Hayashidani S, Tsutsui H, Shiomi T, et al. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002 105 868-873. (Pubitemid 34174929)
8. Bauersachs J, Galuppo P, Fraccarollo D, et al. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme A reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 2001 104 982-985. (Pubitemid 32803872)
9. Bleske BE, Nicklas JM, Bard RL, et al. Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level. J Am Coll Cardiol 2006 47 338-341. (Pubitemid 43063251)
10. Krum H, Ashton E, Reid C, et al. Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure. J Card Fail 2007 13 1-7. (Pubitemid 46330836)
11. Laufs U, Wassmann S, Schackmann S, et al. Beneficial effects of statins in patients with non-ischemic heart failure. Z Kardiol 2004 93 103-108. (Pubitemid 38241500)
12. Node K, Fujita M, Kitakaze M, et al. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 2003 108 839-843. (Pubitemid 37022126)
13. Sola S, Mir MQ, Lerakis S, et al. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 2006 47 332-337. (Pubitemid 43063250)
14. Strey CH, Young JM, Lainchbury JH, et al. Short-term statin treatment improves endothelial function and neurohormonal imbalance in normocholesterolaemic patients with non-ischaemic heart failure. Heart 2006 92 1603-1609. (Pubitemid 44629164)
15. Tousoulis D, Antoniades C, Vassiliadou C, et al. Effects of combined administration of low dose atorvastatin and vitamin E on inflammatory markers and endothelial function in patients with heart failure. Eur J Heart Fail 2005 7 1126-1132. (Pubitemid 41721115)
16. Vrtovec B, Okrajsek R, Golicnik A, et al. Atorvastatin therapy increases heart rate variability, decreases QT variability, and shortens QTc interval duration in patients with advanced chronic heart failure. J Card Fail 2005 11 684-690. (Pubitemid 41797497)
17. Wojnicz R, Wilczek K, Nowalany-Kozielska E, et al. Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels. Am J Cardiol 2006 97 899-904.
18. Xie RQ, Cui W, Liu F, et al. Statin therapy shortens QTc, QTcd, and improves cardiac function in patients with chronic heart failure. Int J Cardiol 2010 140 255-257.
19. Yamada T, Node K, Mine T, et al. Long-term effect of atorvastatin on neurohumoral activation and cardiac function in patients with chronic heart failure: a prospective randomized controlled study. Am Heart J 2007 153 1055.e1-1055e8.
20. Smetanina IN, Vaulin NA, Masenko VP, et al. Short term simvastatin use in patients with heart failure of ischemic origin: changes of blood lipids, markers of inflammation and left ventricular function [in Russian]. Kardiologiia 2006 46 44-49. (Pubitemid 44605767)
21. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007 357 2248-2261. (Pubitemid 350190755)
22. Gissi-HF Investigators, Tavazzi L, Maggioni AP, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008 372 1231-1239.
23. McMurray JJV, Kjekshus J, Gullestad L, et al. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. Circulation 2009 120 2188-2196.
24. Cleland JGF, McMurray JJV, Kjekshus J, et al. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol 2009 54 1850-1859.
25. Pedersen TR, Kjekshus J, Berg K, et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) 1994. Atheroscler Suppl 2004 5 81-87.
26. Takemoto M, Node K, Nakagami H, et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest 2001 108 1429-1437. (Pubitemid 33091980)
27. Feron O, Dessy C, Desager JP, et al. Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 2001 103 113-118. (Pubitemid 32050445)
28. Drexler H, Hornig B,. Endothelial dysfunction in human disease. J Mol Cell Cardiol 1999 31 51-60. (Pubitemid 29078218)
29. Lefer DJ,. Statins as potent anti-inflammatory drugs. Circulation 2002 106 2041-2042.
30. Levine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990 323 236-241. (Pubitemid 20225044)
31. Wiedermann CJ, Beimpold H, Herold M, et al. Increased levels of serum neopterin and decreased production of neutrophil superoxide anions in chronic heart failure with elevated levels of tumor necrosis factor-alpha. J Am Coll Cardiol 1993 22 1897-1901. (Pubitemid 23359650)
32. Patel R, Nagueh SF, Tsybouleva N, et al. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 2001 104 317-324. (Pubitemid 32666954)
33. Martin J, Denver R, Bailey M, et al. In vitro inhibitory effects of atorvastatin on cardiac fibroblasts: implications for ventricular remodelling. Clin Exp Pharmacol Physiol 2005 32 697-701. (Pubitemid 41603148)
34. Ducharme A, Frantz S, Aikawa M, et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 2000 106 55-62. (Pubitemid 30437240)
35. Aikawa M, Rabkin E, Sugiyama S, et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001 103 276-283. (Pubitemid 32095415)
36. Levin ER, Gardner DG, Samson WK,. Mechanisms of disease: natriuretic peptides. N Engl J Med 1998 339 321-328.
37. Uusimaa P, Tokola H, Ylitalo A, et al. Plasma B-type natriuretic peptide reflects left ventricular hypertrophy and diastolic function in hypertension. Int J Cardiol 2004 97 251-256. (Pubitemid 39286844)
38. Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003 107 1278-1283. (Pubitemid 36314411)
39. Goldstein MR,. Effects of lovastatin and pravastatin on coronary artery disease. Ann Intern Med 1994 120 811-812. (Pubitemid 24125306)
40. Tonkin AM,. Management of the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study after the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 1995 76 107C-112C.